Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1998-12-24
2000-10-24
Krass, Frederick
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
436111, 436112, 436163, 436808, 436901, G01N 3348
Patent
active
061368016
ABSTRACT:
Quantitative compliance markers and associated methods for monitoring patient compliance with medication prescriptions associated with compliance markers have been found to eliminate the need for specific quantitative relationships for each new drug tested. Such compliance markers and methods for monitoring patient compliance utilize pharmacologically inert substances, namely the weak acids benzodiazepines, or non-metabolizable substances in association with an underlying drug at a measurable dosage, so as to correlate compliance marker concentration with underlying medication concentration to determine amount of actual medication ingested.
REFERENCES:
patent: 2564247 (1951-08-01), Carson et al.
patent: 3856469 (1974-12-01), Schneider et al.
patent: 3901655 (1975-08-01), Shukla et al.
patent: 4104367 (1978-08-01), Gomez et al.
patent: 4196185 (1980-04-01), Focella et al.
patent: 5047329 (1991-09-01), Suzuki
patent: 5137692 (1992-08-01), Fritz
patent: 5179027 (1993-01-01), Fisher
patent: 5352456 (1994-10-01), Fallon et al.
patent: 5547878 (1996-08-01), Kell
patent: 5776783 (1998-07-01), Kell
Chemical Abstracts 128:317196, "Nefazodone in Major Depression: Adjunctive Benzodiazepine Therapy and Tolerability" Feb. 1998.
Balabanova, et al. Methadone distribution in blood, cerebrospinal fluid, urine and organ tissues, Embase No. 92039431, Austria 1991.
Nilsson et al. Effect of Urinary pH on the disposition of methadone in man, Embase No. 82171209, W. Germany 1982.
Chimera Research & Chemical, Inc., 1996-1997 Product Catalog.
Chimera Research & Chemical, Inc., SG Perfect Urinalysis System Reagent Kits, May 1996.
Prediction of creatinine clearance from plasma creatinine; comparison, M. Robertshaw, K.N. Lai & R Swaminathan, British Journal Clin. Pharmac., 1989, pp. 275-280.
Evaluation of Urine Creatinine as a Marker to Identify Dilute Specimens Being Analyzed for Drugs of Abuse, Barbara Mayer and Gary Hemphill, MRO Alert (Medtox Laboratories, Inc. St. Paul, MN 55112), vol. III No. 6, Aug. 1992, pp. 2-4.
Adulteration of Urine Specimens, John T. Cody, Adapted from Cody JT. Forensic Sci. Rev., 1990, pp. 181-207.
Analytical Toxicology for the MRO, The Medical Review Officer Handbook, 1990, Chapter Ten, pp. 163-172.
Krass Frederick
U. D. Testing, Inc.
LandOfFree
Therapeutic agent with quantitative consumption marker does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agent with quantitative consumption marker, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agent with quantitative consumption marker will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1964196